Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

raloxifene

- PMLiVE

Regulators to improve cooperation on generic drugs

EMA to spearhead information sharing initiative

- PMLiVE

Merck and Lilly enter Keytruda collaboration

Will research anti-PD-1 cancer therapy as part of combination treatment

Bristol Myers Squibb logo

BMS and Lilly to jointly research Opdivo combination

PD-1 inhibitor will be tested with Lilly's galunisertib

- PMLiVE

Novartis completes sale of animal health unit to Lilly

$5.4bn deal is finalised

- PMLiVE

Lilly names head of corporate business development

Promotion for Darren Carroll

- PMLiVE

EU approval for Lilly’s Cyramza in stomach cancer

Follows shortly after the drug's US approval in non-small cell lung cancer

Eli Lilly HQ

Lilly signs $570m deal for next-gen Humalog

Licenses improved version of its insulin blockbuster from Adocia

- PMLiVE

UCB’s $1.53bn generics sale falls through

Advent and Avista Capita back away from bid to acquire Kremers Urban due to unanticipated conflict in timing

Eli Lilly HQ

Lilly reports first pivotal data for Xeljanz rival in arthritis

Baricitinib on course for regulatory filing in late 2015

- PMLiVE

AZ and Lilly start BACE inhibitor trial in Alzheimer’s

Early trials show promise for the BACE inhibitor AZD3293

- PMLiVE

The biosimilars are coming

Lilly on navigating the regulatory pathway for its insulin glargine

- PMLiVE

UCB to sell its US generics business for $1.5bn

Advent International and Avista Capital Partners will take control of Kremers Urban Pharmaceuticals

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links